BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200914
DTEND;VALUE=DATE:20200916
DTSTAMP:20260515T113625
CREATED:20200415T103418Z
LAST-MODIFIED:20200724T145350Z
UID:25038-1600041600-1600214399@www.pharmajournalist.com
SUMMARY:Pre-filled Syringes San Francisco
DESCRIPTION:SMi is proud to announce the inaugural Prefilled Syringes San Francisco event taking place in September 2020. \nThe global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry\, is expected to exceed $9.7 billion by 2025. With that in mind\, this event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation\, new digital technology trends\, human studies and innovative design and delivery systems within the prefilled syringe industry. \n \nAs part of SMi’s leading Injectable conference series\, we will assess digital health and connected devices\, biologics\, biosimilars and biocompatibility for drug device combination products\, platform and device selection\, regulatory insights and explore the West Coast’s biotech innovators. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Device Testing Managers\, Senior Device Engineers\, Heads of Device Development\, Heads of Formulation and Drug Process Development\, and many more. \nPlus\, a workshop on human factors and risk management: \n\nIntegration of Human Factors Engineering processes in risk management saves time and money in product development\nEffective identification of use-related risk helps inform constructive design decisions\nMitigation of use-related risk improves treatment outcomes for end users\nUnderstanding the methods used to assess use-related risk will improve the efficiency and acumen of your organization\n\nBenefits of attending: \n\nEXPLORE the latest industry case studies in platform approaches and connected devices\nGAIN insights from leading industry and regulatory experts on the pre-filled syringes environment\nHEAR from local biotechs of San Francisco and the West Coast to learn about new innovations in the pre-filled syringes space\nENGAGE in the key challenges and topics of the field in two interactive half-day workshops\n\nChairs for 2020: \n\nShannon Clark\, Principal\, UserWise\nSteven Badelt\, Founder and Managing Partner\, Suttons Creek\, Inc.\n\nFeatured 2020 speakers include: \n\nKristina Lauritsen\, Combination Products Regulatory Advisor\, FDA/CDER\nManuela Gazzard\, Group Executive Director Regulatory Services Healthcare\, BSI\nChristine Lynn Lanning\, Distinguished Scientist\, Device Area Leader\, Safety Assessment/Merck & Co.\, Inc\nKhaudeja Bano\, Senior Medical Director\, Abbott Laboratories\nJace Blackburn\, Smart Device Engineer\, Genentech\nMichael Koby\, Senior Principle Scientist\, Pfi zer\nJames Leamon\, Director of Biologics Device Development\, Jazz Pharmaceuticals\nWalter Goodwin\, Device Engineer\, Device Development & Clinical Packaging Engineering\, Gilead Sciences\nKatie Atkinson\, Manager Human Factors Engineering\, Bigfoot Biomedical\n\n\nEARLY-BIRD RATES: \n\nBOOK BY 30TH APRIL AND SAVE £600\nBOOK BY 29TH MAY AND SAVE £300\nBOOK BY 30TH JUNE AND SAVE £200\n\nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk \nLinkedIn: @SMi Pharma\nTwitter: #smipfsusa
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-san-francisco/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200914
DTEND;VALUE=DATE:20200916
DTSTAMP:20260515T113625
CREATED:20200415T104121Z
LAST-MODIFIED:20200416T132625Z
UID:25043-1600041600-1600214399@www.pharmajournalist.com
SUMMARY:Future Pharma 2020
DESCRIPTION:Future Pharma\nSeptember 14 – 15\, 2020\nBoston Marriott Long Wharf\, Boston\, MA\nwww.pharmaforce.wbresearch.com \n \nFuture Pharma is a two-day event that brings together heads of brands and franchises\, marketing\, sales and digital executives from leading pharmaceutical companies in an interactive and energizing setting. It is the only conference designed to help commercial leadership evaluate their personal and non- personal promotions\, align marketing and sales strategies and provide insight on commercial success in a post-pandemic industry landscape. \nWith limited vendor attendance and presentations\, you’ll experience true pharma-to-pharma networking in an interactive format. And by selecting sessions based on the topics you care about most\, you’ll connect with other marketing and sales executives who are focused on having the same\, critical conversations. \nFor more information on Future Pharma 2020\, download the agenda: bit.ly/2Vt69aL \nRegister now and SAVE 25% on your conference pass using our exclusive discount code FP20PJ: https://pharmaforce.wbresearch.com/srspricing
URL:https://www.pharmajournalist.com/event/future-pharma-2020/
LOCATION:Boston Marriott Long Wharf\, 296 State Street\, Boston\, MA\, 02109\, United States
ORGANIZER;CN="Worldwide Business Research":MAILTO:futurepharma@wbresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200914
DTEND;VALUE=DATE:20200917
DTSTAMP:20260515T113625
CREATED:20200629T075629Z
LAST-MODIFIED:20200629T075915Z
UID:26114-1600041600-1600300799@www.pharmajournalist.com
SUMMARY:2nd Annual RAS – Targeted Drug Development – Digital Summit
DESCRIPTION:Via the latest data driven case studies from academic and industry pioneers\, the 2nd RAS Targeted Drug Development Summit (running digitally this year!) will shine a spotlight on optimizing the selectivity and tolerability of your anti-RAS therapies\, exploring novel combination strategies and overcome translational pharmacology challenges to set the stage for the 2nd generation of mutation-targeted RAS modulating therapies yet to come. \n \n\nExplore how to leverage the internal structural biology of RAS mutations in order to produce effective and clinically viable therapies with discussions from E Shaw Research\, The Johns Hopkins University School of Medicine & Hospital for Sick Children\nDeep dive into RAS associated pathways in order to optimize combination therapies with insights from Novartis\, Genentech & Deciphera Oncology\nEvaluate the mechanisms of action and resistance of RAS targets to accelerate target validation and clinical translation with insights fromAbbvie\, PhoreMost & Verastem Oncology\nAdopt novel techniques to successfully target therapeutic vulnerabilities in RAS-driven cancers with lessons learnt from BeiGene\, Genentech\, Revolution Medicines\, Oblique Therapeutics & Aro Biotherapeutics\nExplore the successes and future therapeutic potential of targeting mutation beyond G12C from within the RAS community explored Revolution Medicines\, Francis Crick Institute & MD Anderson Cancer Centre\n\nFollowing the success of RAS-Targeted Drug Discovery Summit in 2019\, we will re-unite the RAS community virtually this coming September with the most comprehensive and definitive conference specifically dedicated to this community. \nJoin 250+ of the leading minds from large pharma\, biotech and academia across the globe who are striving to capitalise on the therapeutic opportunity of targeting RAS through advancing novel mechanisms of action\, improving drug-like properties and accelerating the translation of potent and mutation-targeted 2nd generation RAS targeted therapeutic strategies into human clinical trials.
URL:https://www.pharmajournalist.com/event/2nd-annual-ras-targeted-drug-development-digital-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200915
DTEND;VALUE=DATE:20200919
DTSTAMP:20260515T113625
CREATED:20200818T091000Z
LAST-MODIFIED:20200818T091220Z
UID:26798-1600128000-1600473599@www.pharmajournalist.com
SUMMARY:TIDES: Oligonucleotide & Peptide Therapeutics 2020
DESCRIPTION:The #1 event for oligonucleotide\, peptide\, CRISPR and mRNA therapeutic leaders. Join us for top-notch networking\, high-level industry expert speakers\, innovative company presentations\, interactive scientific poster presentations\, and diverse attendee companies and investors — in a multi-day digital format that you can access from anywhere in the world.
URL:https://www.pharmajournalist.com/event/tides-oligonucleotide-peptide-therapeutics-2020/
LOCATION:100% Virtual
ORGANIZER;CN="Informa Connect":MAILTO:Allison.MacDonald@informa.com
END:VEVENT
END:VCALENDAR